产品封面图
文献支持

BT474细胞系

收藏
  • ¥1320
  • BHcell(博辉生物)
  • H-C035
  • 2026年01月14日
    avatar
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 规格

      T25

    BT474/BT474细胞系/BT474细胞株/BT474人乳腺癌细胞Cell line name BT-474

    Synonyms Bt-474; BT474

    Accession CVCL_0179

    Resource Identification Initiative To cite this cell line use: BT-474 (RRID:CVCL_0179)

    Comments Part of: AKT genetic alteration cell panel (ATCC TCP-1029).

    Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

    Part of: COSMIC cell lines project.

    Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).

    Part of: ERK genetic alteration cell panel (ATCC TCP-1033).

    Part of: JWGray breast cancer cell line panel.

    Part of: ICBP43 breast cancer cell line panel.

    Part of: KuDOS 95 cell line panel.

    Part of: MD Anderson Cell Lines Project.

    Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).

    Population: Caucasian.

    Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); 45.8 hours (PubMed=24389870); ~60-80 hours (CLS=300131); ~100 hours (DSMZ=ACC-64); 92.49 hours (JWGray panel).

    Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).

    Omics: Array-based CGH.

    Omics: CNV analysis.

    Omics: Deep exome analysis.

    Omics: Deep phosphoproteome analysis.

    Omics: Deep proteome analysis.

    Omics: Deep quantitative proteome analysis.

    Omics: DNA methylation analysis.

    Omics: Genome sequenced.

    Omics: Glycoproteome analysis by proteomics.

    Omics: Metabolome analysis.

    Omics: miRNA expression profiling.

    Omics: Protein expression by reverse-phase protein arrays.

    Omics: shRNA library screening.

    Omics: SNP array analysis.

    Omics: Transcriptome analysis by microarray.

    Omics: Transcriptome analysis by RNAseq.

    Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870).

    Derived from site: In situ; Breast; UBERON=UBERON_0000310.

    PubMed=7842014; DOI=10.1038/ng1094-155

    Guan X.-Y., Meltzer P.S., Dalton W.S., Trent J.M.

    Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection.

    Nat. Genet. 8:155-161(1994)

     

    PubMed=9671407; DOI=10.1038/sj.onc.1201814

    Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.

    Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.

    Oncogene 16:2865-2878(1998)

     

    PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B

    Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F., Isola J.J., Larsson C.

    Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.

    Genes Chromosomes Cancer 28:308-317(2000)

     

    PubMed=10969801

    Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.

    Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.

    Cancer Res. 60:4519-4525(2000)

     

    PubMed=11343771; DOI=10.1016/S0165-4608(00)00387-3

    Rummukainen J., Kytola S., Karhu R., Farnebo F., Larsson C., Isola J.J.

    Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping.

    Cancer Genet. Cytogenet. 126:1-7(2001)

     

    PubMed=11687795; DOI=10.1038/ng754

    Snijders A.M., Nowak N.J., Segraves R., Blackwood S., Brown N., Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S., Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N., Pinkel D., Albertson D.G.

    Assembly of microarrays for genome-wide measurement of DNA copy number.

    Nat. Genet. 29:263-264(2001)

     

    PubMed=12353263; DOI=10.1002/gcc.10107

    Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J., Mozziconacci M.-J., Conte N., Murati A., Ginestier C., Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C., Birnbaum D., Chaffanet M.

    Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.

    Genes Chromosomes Cancer 35:204-218(2002)

     

    PubMed=12800145; DOI=10.1002/gcc.10218

    Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.

    A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.

    Genes Chromosomes Cancer 37:333-345(2003)

     

    PubMed=16142302; DOI=10.3892/ijo.27.4.881

    de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., Remacle J.

    Molecular characterization of breast cancer cell lines by a low-density microarray.

    Int. J. Oncol. 27:881-892(2005)

     

    PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853

    Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.

    BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.

    Cancer Res. 66:41-45(2006)

     

    PubMed=16195238; DOI=10.1093/carcin/bgi231

    Hussain-Hakimjee E.A., Peng X.-J., Mehta R.R., Mehta R.G.

    Growth inhibition of carcinogen-transformed MCF-12F breast epithelial cells and hormone-sensitive BT-474 breast cancer cells by 1alpha-hydroxyvitamin D5.

    Carcinogenesis 27:551-559(2006)

     

    PubMed=16417655; DOI=10.1186/bcr1370; PMCID=PMC1413994

    Shadeo A., Lam W.L.

    Comprehensive copy number profiles of breast cancer cell model genomes.

    Breast Cancer Res. 8:R9.1-R9.14(2006)

     

    PubMed=16541312; DOI=10.1007/s10549-006-9186-z

    Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.

    Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.

    Breast Cancer Res. Treat. 99:97-101(2006)

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献

    *发表【中文论文】请标注:由博辉生物科技(广州)有限公司提供; *发表【英文论文】请标注:From Bohui Biological Technology (Guangzhou) Co., Ltd.

    相关实验
    • 【求助】求助!HepG-2细胞系内的p53是野生型的么?

      edwardellen 求助!!! 本人菜鸟,最近开始接触凋亡相关信号,在HepG-2中做实验,有一点很困惑,HepG-2中的p53是野生型的还是突变型的?还是两者都存在?查了一些资料,有些文章之间表达的意思模凌两可。困惑啊! 哪位好心的达人能给我一个确定的答案呢? 另外,是否有做p53相关的牛人能告诉我P53在哪些实验用肿瘤细胞系中是野生型的,在哪些是突变型的? 谢谢!谢谢!谢谢! doctormy

    • 「癌细胞」:是我杀了我?PNAS 这项研究竟让肿瘤自己杀死自己

      )具有相似的分子特性。 图片来源:PNAS BT474 作为 HER2 阳性肿瘤模型 为了确定用于旁分泌研究的最佳肿瘤模型,研究人员评估了两种 HER2 阳性肿瘤细胞系(SKOV3ip 和 BT474)的 HER2 水平,转导效率,抗体表达水平和 TZB 敏感性。结果发现相对于对照细胞系,HER2 水平在 BT474 细胞系中最高。天然腺病毒受体水平在对照 HEK293 细胞中最高,在 A549 和 BT474 细胞中分别降低 57% 和 67%,而在 SKOV3ip 中最低。体外转导效率方面,BT474

    • 【求助】哪个细胞系是研究细胞凋亡的理想工具?

      shao74 最近在做细胞凋亡方面的实验,碰到的问题是手头上的细胞系对凋亡不是很敏感,所以不知哪位有更好的建议,谢谢! freecell 这个不好说啊,看你主要做哪个组织的细胞凋亡,什么因素引起的细胞凋亡。 Fasta921 所以要自己筛选敏感的细胞株啊,不同细胞系对同种基因或药物的耐受性不一样的。 goldendoctor Hela 是比较常用

    图标技术资料

    资料下载:

    BT474(BH-C204).docx 附 (下载 0 次)

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    ATCC细胞库
    2026年03月27日询价
    询价
    北京中源合聚生物科技有限公司
    2026年04月13日询价
    ¥1400
    上海盖宁生物科技有限公司
    2026年03月17日询价
    询价
    上海康朗生物科技有限公司
    2025年07月15日询价
    文献支持
    BT474细胞系
    ¥1320